Thiogenesis Therapeutics' Treatment For Leigh Syndrome Receives FDA Rare Pediatric Disease Designation
() -- Thiogenesis Therapeutics' (TTI.V)on Monday said its lead drug candidate, TTI-0102, for the treatment of Leigh syndrome has been granted Rare Pediatric Disease designation by the US Food and Drug Administration (FDA). The designation provides the company with the potential to receive a priority review voucher, aft